Close Menu

ALK Biomarkers

News and reporting on ALK biomarkers.

Investigators will use Biocept's liquid biopsy tests to detect ALK rearrangements both at baseline and to monitor treatment response and resistance mechanisms.

The IHC test was used in clinical studies that led to Zykadia's approval last week as a first-line option for metastatic NSCLC patients with ALK rearrangements.

The expanded indication makes it a first-line option for metastatic non-small cell lung cancer patients with ALK rearrangements.

A big bump in service revenues made up for a decline in product revenues. The company also trimmed its operating expenses and narrowed its net loss. 

The assay can be used to identify patients suitable for treatment with ALK-targeted therapeutics such as Pfizer's Xalkori.

Pages